Benefit and danger from immunotherapy in myasthenia gravis

Carmelo Rodolico, Giulia Nicocia, Valentina Damato, Giovanni Antonini, Rocco Liguori, Amelia Evoli Stampanoni-B

Risultato della ricerca: Contributo in rivistaArticolo in rivista


In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.
Lingua originaleEnglish
pagine (da-a)1367-1375
Numero di pagine9
RivistaNeurological Sciences
Stato di pubblicazionePubblicato - 2021


  • Checkpoint inhibitors
  • Emerging therapy
  • Immunotherapy
  • Refractory myasthenia gravis


Entra nei temi di ricerca di 'Benefit and danger from immunotherapy in myasthenia gravis'. Insieme formano una fingerprint unica.

Cita questo